Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”
Recent Articles
Regional Hospital Consortiums Hope to Compete for Clinical Trials
In a bid to attract research funding while reducing administrative costs, small hospitals across the U.S. are joining together to create clinical trial consortiums....
Precision Therapy Proves Effective, but Costly
Precision medicine, or treatments tailored to individual patients based on genetic testing and other factors, has shown incredible promise in extending the lives of...
What’s Next for Health Care in a Democratic House?
The results of the midterm elections revealed that affordable health care and lower prescription drug costs are key issues for voters.
Three Republican-leaning states (Utah,...
The Middle Ages: Controversies in the Treatment of Adolescents and Young Adults With Leukemia
Over the past few decades, survival rates for pediatric patients with acute lymphocytic leukemia (ALL) have improved dramatically, with five-year survival rates now often...
Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
Current Issue
November 2018, Volume 4, Issue 13
This issue features a look at the U.S. drug pricing system, attempts to solve physician burnout, and more.
